Literature DB >> 352347

Potent agonist and antagonist analogues of luliberin containing an azaglycine residue in position 10.

A S Dutta, B J Furr, M B Giles, B Valcaccia, A L Walpole.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 352347     DOI： 10.1016/0006-291x(78)91544-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


× No keyword cloud information.
  8 in total

Review 1.  Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.

Authors:  Susan M Cheer; Greg L Plosker; Dene Simpson; Antona J Wagstaff
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

Review 3.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 4.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

5.  The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.

Authors:  R C Stein; M Dowsett; A Hedley; J C Gazet; H T Ford; R C Coombes
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

6.  In Search of NPY Y4R Antagonists: Incorporation of Carbamoylated Arginine, Aza-Amino Acids, or d-Amino Acids into Oligopeptides Derived from the C-Termini of the Endogenous Agonists.

Authors:  Kilian K Kuhn; Timo Littmann; Stefanie Dukorn; Miho Tanaka; Max Keller; Takeaki Ozawa; Günther Bernhardt; Armin Buschauer
Journal:  ACS Omega       Date:  2017-07-14

7.  Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats.

Authors:  P V Maynard; R I Nicholson
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640

8.  Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.

Authors:  R I Nicholson; P V Maynard
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.